Rajratan is the second-largest bead wire manufacturer in Asia (excluding China) and claims to be the largest manufacturer in India. The company which claims to have 20% market share in Thailand has widened its customer base in the USA, Europe and Sri Lanka.
Investing 250 crore for capacity expansion in the next three years.
The company has two manufacturing facilities:
1. Pithampur (Madhya Pradesh, India) 2. Ratchaburi in Thailand.
It is setting up a new 3rd plant in Chennai and expanding the capacity of the plant in Thailand
Capacity :
Pithampur 60000
Thailand 40000 ( expanding 60000)
Chennai 60000 ( setting up new )
Equity
Promoters 65%
Public 35%
Why Chennai ?..It’s a major automotive hub and has leading tyre makers like MRF and Apollo Tyres. This will save import from its Thailand plant to serve Indian customers and since this plant has ports it will open the opportunity for further exports.
Competition:
In India the company competes with Tata Steel (wire division) and Aarti Steels.
Global footprints 👣
Rajratan is the second-largest bead wire manufacturer in Asia (excluding China) and claims to be the largest manufacturer in India.
The company which claims to have 20% market share in Thailand has widened its customer base in the USA, Europe and Sri Lanka
Proxy play ?
Bead wire forms nearly 3 per cent of the cost of making a tyre and is one of the most critical components in a tyre since it is used to hold the tyre to the rim of the wheel.
Excellent Ratios :
CAGR 👌🏻
Future Growth Potential ?
Immense opportunity as it’s niche player and as auto industry reviving this can be super beneficial to #rajratan. Also, it has good expansion plan along with global export opportunities. Going to be an interesting story ahead 🤟🏻
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Praj is not just an Ethanol Play. Found this bit to be the best, creating mind map of optionalities requires in-depth understanding and use of knowledge from multiple domains... @ishmohit1@soicfinance@unseenvalue 👌🏻🤟🏻💯
Unseen Trends in Biotechnology by Mr. Sajal Kapoor
The year ahead offers positive prospects reflecting the strong fundamentals of the global biopharmaceutical industry against a backdrop of potential further disruption due to the second wave of the pandemic.
1. The extension of our strategic collaboration with Bristol Myers Squibb until 2030 will provide scope for new areas of R&D within that relationship.
2. We have initiated multiple expansion and capability-building initiatives. The phase-III expansion of the Hyderabad laboratory is ongoing and will offer capacity for an additional 300 scientists.